Jan‐Philipp Bach

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Richard Dodel, Axel Rominger, Peter Bartenstein et al. · The Lancet Neurology · 2013 · 185 citations

Medicine, Neurology, Pharmacotherapy +11

Projected numbers of people with movement disorders in the years 2030 and 2050

Jan‐Philipp Bach, Uta Ziegler, Günther Deuschl et al. · Movement Disorders · 2011 · 162 citations

Medicine, Geriatric Medicine, Neurology +16

Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson’s Disease

Jan‐Philipp Bach, Maike Gold, David Mengel et al. · PLoS ONE · 2015 · 78 citations · Full text

Natural Sciences, Chemistry, Neuroscience +16

α1-antitrypsin mitigates NLRP3-inflammasome activation in amyloid β1–42-stimulated murine astrocytes

Taraneh Ebrahimi, Marcus Immanuel Rust, Sarah Kaiser et al. · Journal of Neuroinflammation · 2018 · 71 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease

Jan‐Philipp Bach, Oliver Riedel, Jens Klotsche et al. · Journal of the Neurological Sciences · 2011 · 54 citations · Full text

Pharmacy, Neurology, Pharmacoeconomics +14